Carter Eric G
Known title: DirectorCIK: 0001387660
Associated companies
Transaction History
| AEON | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 | View on chart |
| AEON | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 | View on chart |
| AEON | ▲ Buy | Grant | 222,684 | $0 | 6/17/2026 | View on chart |
| AEON | ▲ Buy | Grant | 36,021 | $0 | 8/31/2024 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan
AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.
AEON Biopharma Shares FDA Feedback on ABP-450 Biosimilar Plan. AEON Biopharma received feedback from the FDA following a Type 2b meeting, which helps clarify the development path for its ABP-450 biosimilar candidate. This regulatory update provides specific guidance on the next steps for the company's pipeline. The stock recently appeared on lists of active healthcare names, reflecting market interest in this regulatory progress.